Prokidney (PROK) Return on Sales (2024 - 2026)

Prokidney (PROK) posted quarterly Return on Sales of 1.89% for Q1 2026, down 24.0% year-over-year from 2.48% in Q1 2025, and down 388.51% quarter-over-quarter from 0.39% in Q4 2025.

Prokidney (PROK) Return on Sales (2024 - 2026) Analysis & Trends

Prokidney (PROK) has reported Return on Sales for 3 consecutive years, with 1.89% the latest figure, recorded in Q1 2026.

  • In Q1 2026, Return on Sales fell 24.0% year-over-year to 1.89%; the TTM figure through Mar 2026 stood at 1.4% (up 403.0% YoY), while the FY2025 annual figure was 1.34%, up 2015.0% from the prior year.
  • Return on Sales fell to 1.89% in Q1 2026 per PROK's latest filing, from 0.39% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.39% in Q4 2025 and bottomed at 6.38% in Q4 2024.
  • Historically, Return on Sales has averaged 2.27% across 3 years, with a median of 1.66% in 2025.
  • Annual changes were most pronounced in 2025 — Return on Sales soared 599 bps — and 2026, when it fell 24 bps.
  • Prokidney's Return on Sales stood at 6.38% in 2024, then soared by 94 bps to 0.39% in 2025, then tumbled by 389 bps to 1.89% in 2026.
  • Business Quant data shows PROK's Return on Sales at 1.89% in Q1 2026, 0.39% in Q4 2025, and 1.65% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 0.00%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.00%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 0.00%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.00%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 0.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.00%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 0.00%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.00%
10 Prokidney 679.95 Mn 679.95 Mn - -3.10%

Historic Data

Download Data
DateValue
Jun 30, 2026 -3.10%
Mar 31, 2026 -1.89%
Dec 31, 2025 -0.39%
Sep 30, 2025 -1.65%
Jun 30, 2025 -1.67%
Mar 31, 2025 -1.65%
Dec 31, 2024 -6.38%